Neoletix entered into an exclusive license agreement with Sichuan Yuanda Shuyang for the development

     Beijing, Oct. 1st, 2022 — Neoletix Biotechnology Co., LTD (Neoletix) announced today that it has entered into an exclusive license agreement with Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Grand Life Sciences Group Co.,   for the development and commercialization of Neoletix's recombinant factor VIII (rhFVIII) in the greater China region. rhFVIII is an expensive molecule broadly used in hemophilia A treatment, making it difficult to gainaccess to needed drug especially for low-and middle-income patients. Neoletix has developed a novel manufacturing process covered by patents that are granted in both US and China, as well as by PCT applications. The recombinant FVIII expression level has been increased significantly, as compared to the current international production levels. As the cost of this molecule can be dramatically reduced, it is believed that the rhFVIII developed by Neoletix’ propriety technology will have a major impact onlandscape of hemophilia A prophylaxis and on-demand therapy once the product is on the market.

     Underthe terms of the license agreement, Neoletix will receive an up-front and milestone payment from Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. based upon the achievement of specified development, regulatory and commercialization goals. Upon commercialization, Neoletix will be also entitled to a tiered royalty on sales in defined territory. Sichuan Yuanda Shuyang PharmaceuticalCo., Ltd. will be responsible for all clinical development, manufacturing, and commercialization activities and costs.